norfloxacin has been researched along with Osteomyelitis in 5 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Osteomyelitis: INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Norfloxacin (NFLX), a new quinolone antibiotic agent, was evaluated for its efficacy in experimental osteomyelitis in rabbits." | 7.68 | [Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits]. ( Aijima, H; Kaetsu, M; Okada, J, 1992) |
| "Pefloxacin was evaluated in the treatment of bone infections." | 5.27 | The diffusion of pefloxacin into bone and the treatment of osteomyelitis. ( Bernard, E; Dellamonica, P; Etesse, H; Garraffo, R, 1986) |
| "Norfloxacin (NFLX), a new quinolone antibiotic agent, was evaluated for its efficacy in experimental osteomyelitis in rabbits." | 3.68 | [Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits]. ( Aijima, H; Kaetsu, M; Okada, J, 1992) |
| "Following a summary of the main bacteriological and pharmacokinetic properties of this new quinolone derivative, the author reviews the results obtained with pefloxacine in the treatment of urinary tract infection, gonococcal urethritis, and bronchopulmonary, surgical, gynaecological, bone, soft tissue, neuromeningeal and ENT infections." | 3.67 | [Pefloxacin: evaluation and clinical prospects]. ( Modaï, J, 1986) |
| "Pefloxacin was evaluated in the treatment of bone infections." | 1.27 | The diffusion of pefloxacin into bone and the treatment of osteomyelitis. ( Bernard, E; Dellamonica, P; Etesse, H; Garraffo, R, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, J | 1 |
| Kaetsu, M | 1 |
| Aijima, H | 1 |
| Yu, D | 1 |
| Tsai, CL | 1 |
| Wong, J | 1 |
| Fox, JL | 1 |
| Neu, HC | 1 |
| Dellamonica, P | 1 |
| Bernard, E | 1 |
| Etesse, H | 1 |
| Garraffo, R | 1 |
| Modaï, J | 1 |
5 other studies available for norfloxacin and Osteomyelitis
| Article | Year |
|---|---|
[Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits].
Topics: Animals; Drug Evaluation; Drug Resistance, Microbial; Male; Norfloxacin; Osteomyelitis; Rabbits; Sta | 1992 |
Hydroxyapatite cement based drug delivery systems: drug release in vitro.
Topics: Bone Cements; Cephalexin; Delayed-Action Preparations; Fractures, Open; Hydroxyapatites; In Vitro Te | 1991 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
The diffusion of pefloxacin into bone and the treatment of osteomyelitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Biopsy; Bone and Bones; Calcium; Chromatography, High Pressure L | 1986 |
[Pefloxacin: evaluation and clinical prospects].
Topics: Bacterial Infections; Evaluation Studies as Topic; Female; Humans; Lung Diseases; Male; Meningitis; | 1986 |